The association of smoking and socioeconomic status on cutaneous melanoma: a population-based, data-linkage, case-control study.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
05 2020
Historique:
accepted: 08 09 2019
pubmed: 19 9 2019
medline: 15 5 2021
entrez: 19 9 2019
Statut: ppublish

Résumé

Previous studies have identified an inverse association between melanoma and smoking; however, data from population-based studies are scarce. To determine the association between smoking and socioeconomic (SES) on the risk of development of melanoma. Furthermore, we sought to determine the implications of smoking and SES on survival. We conducted a population-based case-control study. Cases were identified from the Welsh Cancer Intelligence and Surveillance Unit (WCISU) during 2000-2015 and controls from the general population. Smoking and SES were obtained from data linkage with other national databases. The association of smoking status and SES on the incidence of melanoma were assessed using binary logistic regression. Multivariate survival analysis was performed on a melanoma cohort using a Cox proportional hazard model using survival as the outcome. During 2000-2015, 9636 patients developed melanoma. Smoking data were obtained for 7124 (73·9%) of these patients. There were 26 408 controls identified from the general population. Smoking was inversely associated with melanoma incidence [odds ratio (OR) 0·70, 95% confidence interval (CI) 0·65-0·76]. Smoking was associated with an increased overall mortality [hazard ratio (HR) 1·30, 95% CI 1·09-1·55], but not associated with melanoma-specific mortality. Patients with higher SES had an increased association with melanoma incidence (OR 1·58, 95% CI 1·44-1·73). Higher SES was associated with an increased chance of both overall (HR 0·67, 95% CI 0·56-0·81) and disease-specific survival (HR 0·69, 95% CI 0·53-0·90). Our study has demonstrated that smoking appeared to be associated with reduced incidence of melanoma. Although smoking increases overall mortality, no association was observed with melanoma-specific mortality. Further work is required to determine if there is a biological mechanism underlying this relationship or an alternative explanation, such as survival bias. What's already known about this topic? Previous studies have been contradictory with both negative and positive associations between smoking and the incidence of melanoma reported. Previous studies have either been limited by publication bias because of selective reporting or underpowered. What does this study add? Our large study identified an inverse association between smoking status and melanoma incidence. Although smoking status was negatively associated with overall disease survival, no significant association was noted in melanoma-specific survival. Socioeconomic status remains closely associated with melanoma. Although higher socioeconomic populations are more likely to develop the disease, patients with lower socioeconomic status continue to have a worse prognosis.

Sections du résumé

BACKGROUND
Previous studies have identified an inverse association between melanoma and smoking; however, data from population-based studies are scarce.
OBJECTIVES
To determine the association between smoking and socioeconomic (SES) on the risk of development of melanoma. Furthermore, we sought to determine the implications of smoking and SES on survival.
METHODS
We conducted a population-based case-control study. Cases were identified from the Welsh Cancer Intelligence and Surveillance Unit (WCISU) during 2000-2015 and controls from the general population. Smoking and SES were obtained from data linkage with other national databases. The association of smoking status and SES on the incidence of melanoma were assessed using binary logistic regression. Multivariate survival analysis was performed on a melanoma cohort using a Cox proportional hazard model using survival as the outcome.
RESULTS
During 2000-2015, 9636 patients developed melanoma. Smoking data were obtained for 7124 (73·9%) of these patients. There were 26 408 controls identified from the general population. Smoking was inversely associated with melanoma incidence [odds ratio (OR) 0·70, 95% confidence interval (CI) 0·65-0·76]. Smoking was associated with an increased overall mortality [hazard ratio (HR) 1·30, 95% CI 1·09-1·55], but not associated with melanoma-specific mortality. Patients with higher SES had an increased association with melanoma incidence (OR 1·58, 95% CI 1·44-1·73). Higher SES was associated with an increased chance of both overall (HR 0·67, 95% CI 0·56-0·81) and disease-specific survival (HR 0·69, 95% CI 0·53-0·90).
CONCLUSIONS
Our study has demonstrated that smoking appeared to be associated with reduced incidence of melanoma. Although smoking increases overall mortality, no association was observed with melanoma-specific mortality. Further work is required to determine if there is a biological mechanism underlying this relationship or an alternative explanation, such as survival bias. What's already known about this topic? Previous studies have been contradictory with both negative and positive associations between smoking and the incidence of melanoma reported. Previous studies have either been limited by publication bias because of selective reporting or underpowered. What does this study add? Our large study identified an inverse association between smoking status and melanoma incidence. Although smoking status was negatively associated with overall disease survival, no significant association was noted in melanoma-specific survival. Socioeconomic status remains closely associated with melanoma. Although higher socioeconomic populations are more likely to develop the disease, patients with lower socioeconomic status continue to have a worse prognosis.

Identifiants

pubmed: 31529485
doi: 10.1111/bjd.18526
pmc: PMC7383980
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1136-1147

Subventions

Organisme : Wellcome Trust
ID : 205039/Z/16/Z
Pays : United Kingdom
Organisme : Tenovus
ID : iGrant
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 British Association of Dermatologists.

Références

Br J Dermatol. 2015 Apr;172(4):885-915
pubmed: 25354495
Health Stat Q. 2006 Winter;(32):19-34
pubmed: 17165467
BMC Med Inform Decis Mak. 2017 Jan 5;17(1):2
pubmed: 28056955
Lancet. 2005 Apr 16-22;365(9468):1429-33
pubmed: 15836892
BMC Med Inform Decis Mak. 2009 Jan 16;9:3
pubmed: 19149883
J Biomed Inform. 2014 Aug;50:196-204
pubmed: 24440148
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):874-881
pubmed: 29789324
Am J Epidemiol. 1985 Oct;122(4):606-19
pubmed: 4025303
Br J Cancer. 2018 Jul;119(1):114-120
pubmed: 29899391
J Clin Invest. 2005 Nov;115(11):3166-76
pubmed: 16239965
Br J Dermatol. 2014 Apr;170(4):787-93
pubmed: 24359255
Br J Dermatol. 2015 Dec;173(6):1540-3
pubmed: 26134854
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Ann Surg Oncol. 2017 Aug;24(8):2089-2094
pubmed: 28224364
Cancer Biol Ther. 2009 Nov;8(21):1986-93
pubmed: 19783903
BMC Health Serv Res. 2009 Sep 04;9:157
pubmed: 19732426
Lancet Oncol. 2009 Nov;10(11):1033-4
pubmed: 19891056
Pigment Cell Melanoma Res. 2010 Jun;23(3):338-51
pubmed: 20230483
Nicotine Tob Res. 2006 Aug;8(4):487-98
pubmed: 16920646
Br J Dermatol. 2013 Jan;168(1):154-61
pubmed: 23039760
Anticancer Res. 2008 Nov-Dec;28(6B):4003-8
pubmed: 19192664
Arch Dermatol. 1997 Jul;133(7):823-5
pubmed: 9236519
Dermatol Online J. 2013 Aug 15;19(8):19258
pubmed: 24021437
Int J Cancer. 2011 May 15;128(10):2251-60
pubmed: 21207412
Postgrad Med J. 2000 May;76(895):273-9
pubmed: 10775279
Soc Sci Med. 1984;19(4):475-8
pubmed: 6484633
J Crohns Colitis. 2014 Aug;8(8):717-25
pubmed: 24636140
Transl Neurodegener. 2015 Nov 03;4:21
pubmed: 26535116
BMJ. 1993 Oct 9;307(6909):911
pubmed: 8241856
Cancer Med. 2016 Aug;5(8):2048-60
pubmed: 27228302
Int J Epidemiol. 2012 Dec;41(6):1694-705
pubmed: 23064412
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639

Auteurs

J A G Gibson (JAG)

Reconstructive Surgery& Regenerative Medicine Research Group, Institute of Life Science, Swansea University Medical School, Swansea, U.K.
The Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, U.K.

T D Dobbs (TD)

Reconstructive Surgery& Regenerative Medicine Research Group, Institute of Life Science, Swansea University Medical School, Swansea, U.K.
The Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, U.K.

R Griffiths (R)

Health Data Research UK, Swansea University, Swansea, U.K.

J Song (J)

Health Data Research UK, Swansea University, Swansea, U.K.

A Akbari (A)

Patient and Population Health and Informatics Research and, Swansea University Medical School, Swansea, U.K.
Administrative Data Research Centre Wales, Swansea University Medical School, Swansea, U.K.
Health Data Research UK, Swansea University, Swansea, U.K.

S Whitaker (S)

Department of Dermatology, Singleton Hospital, Swansea, U.K.

A Watkins (A)

Patient and Population Health and Informatics Research and, Swansea University Medical School, Swansea, U.K.
Health Data Research UK, Swansea University, Swansea, U.K.

S M Langan (SM)

Health Data Research UK, London, U.K.
London School of Hygiene & Tropical Medicine, London, U.K.

H A Hutchings (HA)

Patient and Population Health and Informatics Research and, Swansea University Medical School, Swansea, U.K.

R A Lyons (RA)

Patient and Population Health and Informatics Research and, Swansea University Medical School, Swansea, U.K.
Administrative Data Research Centre Wales, Swansea University Medical School, Swansea, U.K.
Health Data Research UK, Swansea University, Swansea, U.K.

I S Whitaker (IS)

Reconstructive Surgery& Regenerative Medicine Research Group, Institute of Life Science, Swansea University Medical School, Swansea, U.K.
The Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH